List of works - Aline Renneville

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

scientific article published on 07 February 2019

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

scientific article published on 26 May 2016

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy

scientific article published on 09 August 2011

Acute myeloid leukemia with translocation t(3;5): new molecular insights.

scientific article published on 12 February 2013

B7-H3 protein expression in acute myeloid leukemia

scientific article published on 17 September 2015

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

scientific article

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

scientific article published on 01 October 2008

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial

scientific article

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

scientific article published on 22 February 2018

Clonal architecture of chronic myelomonocytic leukemias

scientific article published on 14 January 2013

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes

scientific article

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

scientific article published on 20 June 2011

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

scientific article published on 01 March 2011

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

scientific article published on December 2015

Exome analysis of treatment-related AML after APL suggests secondary evolution

scientific article published on 22 November 2018

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

scientific article

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

scientific article published on 18 April 2018

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

scientific article published on 19 October 2010

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

scientific article

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

scientific article published on 21 October 2015

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

scholarly article by Ashfaq Ali et al published 26 February 2018 in Leukemia

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

scientific article published on 8 April 2009

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

scientific article published on 13 October 2015

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

scientific article published on 31 December 2014

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

scientific article published on 20 May 2010

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

scientific article

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis

scientific article published on 04 August 2012

Linezolid induces ring sideroblasts

scientific article published on November 2013

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

scientific article

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

scientific article published on 26 March 2013

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

scientific article

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

scientific article published on 29 November 2011

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA

scientific article published on 08 March 2014

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

scientific article

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

scientific article

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

scientific article published on 8 November 2017

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

scientific article

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

scientific article published on 28 May 2012

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

scientific article

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

scientific article

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

scientific article published on 25 April 2018

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

scientific article

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

scientific article

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

scientific article published on 9 October 2015

Quantification of JAK2V617F mutation by next-generation sequencing technology.

scientific article published on 13 May 2013

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

scientific article

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

scientific article published on 16 July 2009

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

scientific article

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

scientific article

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

scientific article published on 25 February 2020

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association

scientific article

List of works by Aline Renneville

A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

Acquired alpha thalassemia myelodyslastic/myeloproliferative syndrome (ATMDS): evolution on hypomethylating agent therapy

Acute myeloid leukemia with translocation t(3;5): new molecular insights.

B7-H3 protein expression in acute myeloid leukemia

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Clonal architecture of chronic myelomonocytic leukemias

Comparison of TP53 mutations screening by functional assay of separated allele in yeast and next-generation sequencing in myelodysplastic syndromes

Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study

Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Exome analysis of treatment-related AML after APL suggests secondary evolution

Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations.

Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia

Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia.

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Incidence of ATRX mutations in myelodysplastic syndromes, the value of microcytosis.

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis

Linezolid induces ring sideroblasts

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations.

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.

Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA

Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosis.

Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia

Outcome of treatment after first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802 trial

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.

Quantification of JAK2V617F mutation by next-generation sequencing technology.

Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.

Slow relapse in acute myeloid leukemia with inv(16) or t(16;16).

Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association